Dear editor,

We have prepared a manuscript that represents our analysis regarding our study. Gliomas are more than 80% of all primary brain cancers and 24% of all brain tumors. In 2021, the new edition of WHO - Classification of Tumors of the Central Nervous System (WHO- CTCNS) established genetic and molecular aspects to the analysis since they could be correlated to characteristics of tumor behavior and clinical-epidemiological features. However, there are few studies correlating molecular analysis to the clinical follow-up of patients in Brazil. We performed a preliminary, observational, prospective and descriptive study that aims to obtain and to compare clinical-epidemiological data to molecular markers of patients in follow-up at Central Hospital of Santa Casa de São Paulo (HC-ISCMSP).


Correspondence: E-mail: thaistjareno@gmail.com

* Paper presented at the Panels Surgical Award at the Scientific Awards of the XLII Congresso Médico-Universitário da Faculdade de Medicina da Universidade de São Paulo - 2nd place award - São Paulo (SP - Brazil); 6 - 8 October 2023.

1. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Departamento de Cirurgia, Disciplina de Neurocirurgia. ORCID: https://orcid.org/0009-0006-3125-3299 E-mail: thaistjareno@gmail.com
2. Universidade Estadual de Campinas (UNICAMP), Instituto de Biologia, Departamento de Biologia Estrutural e Funcional; Universidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Farmacêuticas, Laboratório de Desenvolvimento de Fármacos. ORCID: https://orcid.org/0000-0001-6150-3582 E-mail: nataliabarreto.jdi@gmail.com
3. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Departamento de Cirurgia, Disciplina de Neurocirurgia. ORCID: https://orcid.org/0009-0007-6311-3116 E-mail: marques.gika@gmail.com
4. Universidade Estadual de Campinas (UNICAMP), Instituto de Biologia, Departamento de Biologia Estrutural e Funcional; Universidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Farmacêuticas, Laboratório de Desenvolvimento de Fármacos. ORCID: https://orcid.org/0000-0001-8804-497X E-mail: raposo@unicamp.br
5. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Departamento de Cirurgia, Disciplina de Neurocirurgia; Irmandade da Santa Casa de Misericórdia de São Paulo, Departamento de Cirurgia, Disciplina de Neurocirurgia. ORCID: https://orcid.org/0000-0002-7723-4396 E-mail: jose.veiga@santacasasp.org.br
6. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Departamento de Cirurgia, Disciplina de Neurocirurgia; Irmandade da Santa Casa de Misericórdia de São Paulo, Departamento de Cirurgia, Disciplina de Neurocirurgia; Universidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Farmacêuticas, Laboratório de Desenvolvimento de Fármacos. ORCID: https://orcid.org/0000-0002-6539-6718 E-mail: drjoaovitorino@gmail.com

Dear Editor,

We have prepared a manuscript that represents our analysis regarding our study. Gliomas are more than 80% of all primary brain cancers and 24% of all brain tumors. In 2021, the new edition of WHO - Classification of Tumors of the Central Nervous System (WHO- CTCNS) established genetic and molecular aspects to the analysis since they could be correlated to characteristics of tumor behavior and clinical-epidemiological features. However, there are few studies correlating molecular analysis to the clinical follow-up of patients in Brazil. We performed a preliminary, observational, prospective and descriptive study that aims to obtain and to compare clinical-epidemiological data to molecular markers of patients in follow-up at Central Hospital of Santa Casa de São Paulo (HC-ISCMSP).
The most common subtype of gliomas (58.4%) is glioblastoma, known among malignant brain tumors as the most aggressive\(^1\). The WHO - CTCNS 2021 brought in the IDH-1 marker as a watershed for diagnosing glioblastoma and other high-grade astrocytomas. Currently, the diagnosis of glioblastoma - the highest grade tumor - is given by wild-type IDH-1 tumors. All IDH-mutant diffuse astrocytic tumors are graded as 2, 3, or 4 and are considered a single type (astrocytoma, IDH-mutant)\(^2\). This oncogene plays roles in Krebs circle and cellular homeostasis. It’s believed that the IDH mutants can change cancer metabolism, epigenetic shift and therapy resistance\(^2\).

As an initial experience, the study denotes to enlighten the clinical-histopathological-molecular features of these tumors in the Brazilian scenery. It engages our research progression as the sample is being expanded for further findings on the associations.

Sincerely,

Thaís Tuasca Jareño - lead author, participation in study design, data collection, or data analysis/interpretation; involvement in drafting or revising the manuscript; approval of the final version of the manuscript for publication; responsibility for the accuracy and integrity of all aspects of the research. Natália Barreto dos Santos - participation in study design, data analysis/interpretation; involvement in drafting or revising the manuscript; approval of the final version of the manuscript for publication. Giovanna Marques Antunes - participation in data collection, involvement in reviewing the manuscript. Catarina Rapôso - involved in drafting or revising the manuscript; approval of the final version of the manuscript for publication. José Carlos Esteves Veiga - involvement in drafting or revising the manuscript; approval of the final version of the manuscript for publication. João Luiz Vitorino Araujo - project supervisor, participation in study design, data collection, or data analysis/interpretation; involvement in drafting or revising the manuscript; approval of the final version of the manuscript for publication; responsibility for the accuracy and integrity of all aspects of the research.

REFERENCES


Received: 2024, Mayo 07
Accepted: 2024, Mayo 09